<DOC>
	<DOCNO>NCT01812551</DOCNO>
	<brief_summary>Cystic fibrosis ( CF ) -- autosomal recessive genetic disease affect 60,000 individual worldwide , include 3,800 Italy -- often associate low bone mineral mass . The current aggressive therapy ensure much long survival CF patient lead high frequency osteoporosis bone fracture , serious problem affect quality life , also hinder therapeutic measure . The aim study , conduct large group child , adolescent young adult CF , evaluation bone mass change 1 year simple treatment RDA-adjusted dietary calcium plus 25-OH vitamin D supplementation , feasibility efficacy alendronate treatment ( another year ) patient respond calcium + 25-OH vitamin D alone .</brief_summary>
	<brief_title>Treatment Low Bone Density Cystic Fibrosis .</brief_title>
	<detailed_description>The study include 2 phase . Phase 1 ( 1-year open-label observational study ) : follow baseline evaluation , bone mass change study simple therapy adequate calcium intake 25-OH vitamin D supplement eligible subject ( N=171 ) . Phase 2 ( 1-year double-blind , randomize , placebo-controlled , parallel group study ) : 128 subject show insufficient response calcium + 25-OH vitamin D alone ( bone mass increase &lt; 5 % ) end Phase 1 , randomize 2 group assigned alendronate treatment ( N=65 ) placebo ( N=63 ) ( addition calcium 25-OH vitamin D Phase 1 ) . The study carry Coordinator 's Institution ( Istituto Auxologico Italiano ) collaboration Regional Reference Centers CF Italy .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>age 230 year clinically stable condition regular menses female low Bone Mineral Apparent Density age ( define BMAD Zscore ≤2.0 age ≤18 year ≤2.5 age &gt; 18 year ) . two episode hypercalcemia and/or hypercalciuria contraindication 25OH vitamin D alendronate treatment recent transplantation disease medication ( glucocorticoid except ) associate bone loss .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>cystic fibrosis</keyword>
	<keyword>child</keyword>
	<keyword>adolescent</keyword>
	<keyword>low bone mass</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>alendronate</keyword>
	<keyword>fracture</keyword>
</DOC>